Cart
sales@molnova.com
Senexin-A
CAS No. 1366002-50-7
Senexin-A( Senexin A )
Catalog No. M11512 CAS No. 1366002-50-7
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 65 | In Stock |
|
| 5MG | 104 | In Stock |
|
| 10MG | 151 | In Stock |
|
| 25MG | 295 | In Stock |
|
| 50MG | 537 | In Stock |
|
| 100MG | 767 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSenexin-A
-
NoteResearch use only, not for human use.
-
Brief DescriptionA selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
DescriptionA selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively; inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells; suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts and reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.
-
In Vitro——
-
In Vivo——
-
SynonymsSenexin A
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1366002-50-7
-
Formula Weight274.32
-
Molecular FormulaC17H14N4
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥100 mg/mL
-
SMILESN#CC1=CC2=C(NCCC3=CC=CC=C3)N=CN=C2C=C1
-
Chemical Name6-Quinazolinecarbonitrile, 4-[(2-phenylethyl)amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Porter DC, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804.
2. McDermott MS, et al. Oncotarget. 2017 Feb 21;8(8):12558-12575.
molnova catalog
related products
-
NVP-2
NVP-2 is a?potent, selective, ATP-competitive CDK9 inhibitor with IC50 of <0.514 nM (CDK9/CyclinT).
-
SU-9516 (b)
SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
-
CDK9-IN-4d
CDK9-IN-1 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition.
